Clinical Trial Update: A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating the safety, pharmacokinetics, and efficacy of the combination of tafasitamab and parsaclisib in relapsed/refractory chronic lymphocyt…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• Monjuvi (tafasitamab)
• Parsaclisib (parsaclisib)

Snippet

Sponsor: Incyte Corporation | Conditions: Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2026-01-29